Science Corp. raises $400 million to take its PRIMA retinal implant to the US
The Series D, reportedly at a $3.5 billion valuation, funds PRIMA's wider European rollout, a planned US launch through the FDA's Humanitarian Device Exemption and Science's biohybrid brain interface program.